مباشر
FierceBiotechWith ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity raceFierceBiotechThe new standard for trusted AI in biopharmaEndpoints NewsPost-Hoc Live: How much is everyone in biopharma getting paid?BioWorldAppointments and advancements for June 9, 2026BioWorldFinancings for June 9, 2026BioWorldIn the clinic for June 9, 2026BioWorldOther news to note for June 9, 2026BioWorldRegulatory actions for June 9, 2026Endpoints NewsWuXi AppTec added to Pentagon list of companies linked to Chinese militaryMerck & Co.Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study - The Pharma LetterFierceBiotechBial bails after Parkinson’s fail, axing asset over phase 2 missMerck & Co.Major US Pharma and Biotech Deals of the Past Decade - Global Banking & Finance Review
BioWorld ٥ ديسمبر ٢٠٢٥

New FGFR3 inhibitors disclosed in Onco3r Therapeutics patent

New FGFR3 inhibitors disclosed in Onco3r Therapeutics patent

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.